Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2025
0mins
Source: PRnewswire
Aadi Bioscience's Strategic Transactions: Aadi Bioscience has proposed the sale of its FYARRO product and associated infrastructure to Kaken Pharmaceuticals for $100 million, along with a $100 million PIPE financing to support the in-licensing of an antibody drug conjugate (ADC) portfolio from WuXi Biologics. The company aims to close these transactions by Q1 2025, pending stockholder approval.
Board's Recommendation to Stockholders: Aadi's Board encourages stockholders to vote "FOR" all proposals at the upcoming Special Meeting on February 28, 2025, emphasizing that these strategic moves are essential for maximizing long-term value and revitalizing the company's oncology therapy pipeline.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
